Results 21 to 30 of about 22,968 (195)

A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers. [PDF]

, 2019
Cohesin is a multiprotein ring that is responsible for cohesion of sister chromatids and formation of DNA loops to regulate gene expression. Genomic analyses have identified that the cohesin subunit STAG2 is frequently inactivated by mutations in cancer.
Ashworth, Alan, Goode, Benjamin, Mondal, Gourish, Solomon, David A, Stevers, Meredith   +4 more
core   +2 more sources

Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance

Cancer Biology & Medicine, 2019
Objective Lack of effective therapies remains a problem in the treatment of oral squamous cell carcinoma (OSCC), especially in patients with advanced tumors.
Nur Syafinaz Zainal, Bernard Kok Bang Lee, Zheng Wei Wong, Iuan Sheau Chin, Pei San Yee, Chai Phei Gan, Kein Seong Mun, Zainal Ariff Abdul Rahman, J. Silvio Gutkind, Vyomesh Patel, Sok Ching Cheong   +10 more
doaj   +1 more source

Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells [PDF]

, 2017
Purpose: Early detection is essential for treatment plans before onset of metastatic disease. Our purpose was to demonstrate feasibility to detect and monitor estrogen receptor 1 (ESR1) gene mutations at the single circulating tumor cell (CTC) level in ...
Austin, Laura, Capoluongo, Ettore, Cristofanilli, Massimo, Fortina, Paolo, Knudsen, Karen E., Mu, Zhaomei, Nguyen, Thomas, Paolillo, Carmela, Rossi, Giovanna, Schiewer, Matthew J.   +9 more
core   +3 more sources

FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells

Cells, 2021
Resistance to CDK4/6 inhibitors (CDKis) is emerging as a clinical challenge. Identification of the factors contributing to CDKi resistance, with mechanistic insight, is of pivotal significance.
Qiong Cheng, Zhikun Ma, Yujie Shi, Amanda B. Parris, Lingfei Kong, Xiaohe Yang   +5 more
doaj   +1 more source

In vivo E2F reporting reveals efficacious schedules of MEK1/2–CDK4/6 targeting and mTOR–s6 resistance mechanisms [PDF]

, 2018
Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in vivo
Aplin, Andrew E., Cheng, Phil F., Chervoneva, Inna, Davies, Michael A., Dummer, Reinhard, Ertel, Adam, Fortina, Paolo, Hookim, Kim, Kleiber, Ines, Kwong, Lawrence N., Levesque, Mitch P., Nikbakht, Neda, Patel, Prem, Purwin, Timothy J., Teh, Jessica L. F.   +14 more
core   +1 more source

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer

Patient Preference and Adherence, 2023
Nicole M Engel-Nitz,1 Mary G Johnson,1 Michael P Johnson,1 Ashley S Cha-Silva,2 Samantha K Kurosky,2 Xianchen Liu2 1Optum, Eden Prairie, MN, 55344, USA; 2Pfizer Inc, New York, NY, 10017, USACorrespondence: Nicole M Engel-Nitz, HEOR | Optum Life Sciences,
Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X   +5 more
doaj  

Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells

Cancer Cell International, 2020
Background Aberrant activity of cell cycle proteins is one of the key somatic events in non-small cell lung cancer (NSCLC) pathogenesis. In most NSCLC cases, the retinoblastoma protein tumor suppressor (RB) becomes inactivated via constitutive ...
Lindsey R. Conroy, Pawel Lorkiewicz, Liqing He, Xinmin Yin, Xiang Zhang, Shesh N. Rai, Brian F. Clem   +6 more
doaj   +1 more source

Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma

BMC Medicine, 2022
Background Deregulation of cell-cycle pathway is ubiquitously observed in human papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC).
Ziyue Gu, Chaoji Shi, Jiayi Li, Yong Han, Bao Sun, Wuchang Zhang, Jing Wu, Guoyu Zhou, Weimin Ye, Jiang Li, Zhiyuan Zhang, Rong Zhou   +11 more
doaj   +1 more source

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer

Current Oncology, 2022
Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human ...
Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy   +3 more
doaj   +1 more source

Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling

Current Issues in Molecular Biology
Palbociclib is a cyclin-dependent kinase 4/6 inhibitor and a commonly used antitumor drug. Many cancers are susceptible to palbociclib resistance, however, the underlying metabolism mechanism and extent of resistance to palbociclib are unknown.
Lulu Yang, Yajun Yue, Zhendong Wang, You Jiang, Zhichao Xue, Yongzhuo Zhang   +5 more
doaj   +1 more source